These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7795272)

  • 41. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
    Weiss GR; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek LV; Whaley F; Patricia E; Von Hoff DD; O'Dwyer P
    Clin Cancer Res; 1998 Jan; 4(1):53-9. PubMed ID: 9516952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I clinical and pharmacokinetic trial of flavone acetic acid.
    Havlin KA; Kuhn JG; Craig JB; Boldt DH; Weiss GR; Koeller J; Harman G; Schwartz R; Clark GN; Von Hoff DD
    J Natl Cancer Inst; 1991 Jan; 83(2):124-8. PubMed ID: 1703237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I clinical and pharmacokinetic study of LY 195448.
    Cassidy J; Lewis C; Adams L; Setanoians A; Bayssas M; Boder GG; Rankin EM; Kaye SB
    Cancer Chemother Pharmacol; 1989; 24(4):233-7. PubMed ID: 2752504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTG.
    Cassidy J; Graham MA; Ten Bokkel Huinink W; McDaniel C; Setanoians A; Rankin EM; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1993; 31(5):395-400. PubMed ID: 8431974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical pharmacology of deoxyspergualin in patients with advanced cancer.
    Muindi JF; Lee SJ; Baltzer L; Jakubowski A; Scher HI; Sprancmanis LA; Riley CM; Vander Velde D; Young CW
    Cancer Res; 1991 Jun; 51(12):3096-101. PubMed ID: 2039989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of deoxyspergualin in metastatic breast cancer.
    Dhingra K; Valero V; Gutierrez L; Theriault R; Booser D; Holmes F; Buzdar A; Fraschini G; Hortobagyi G
    Invest New Drugs; 1994; 12(3):235-41. PubMed ID: 7896543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
    Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper MA; Grasela D; Buzdar A; Valero V
    Cancer Res; 1995 Jul; 55(14):3060-7. PubMed ID: 7606728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of NKT-01.
    Tamura K; Niitani H; Oguro M; Ohno R; Sanpi K; Majima H; Masaoka T; Kimura I; Inagaki J; Suzuoki Y
    Cancer Chemother Pharmacol; 1995; 36(3):189-94. PubMed ID: 7781137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 15-deoxyspergualin: from cytostasis to immunosuppression.
    Dickneite G; Schorlemmer HU; Weinmann E; Sedlacek HH
    Behring Inst Mitt; 1988 Apr; (82):231-9. PubMed ID: 3044340
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
    Havlin KA; Kuhn JG; Koeller J; Boldt DH; Craig JB; Brown TD; Weiss GR; Cagnola J; Phillips J; Harman G
    Anticancer Drugs; 1995 Apr; 6(2):229-36. PubMed ID: 7795272
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.